CA2935630A1 - Frizzled receptor antibodies for treatment of cancer - Google Patents
Frizzled receptor antibodies for treatment of cancer Download PDFInfo
- Publication number
- CA2935630A1 CA2935630A1 CA2935630A CA2935630A CA2935630A1 CA 2935630 A1 CA2935630 A1 CA 2935630A1 CA 2935630 A CA2935630 A CA 2935630A CA 2935630 A CA2935630 A CA 2935630A CA 2935630 A1 CA2935630 A1 CA 2935630A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- tumor
- seq
- antigen
- isolated antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461922893P | 2014-01-02 | 2014-01-02 | |
| US61/922,893 | 2014-01-02 | ||
| PCT/IL2015/050009 WO2015101998A1 (en) | 2014-01-02 | 2015-01-01 | Frizzled receptor antibodies for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2935630A1 true CA2935630A1 (en) | 2015-07-09 |
Family
ID=53493369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2935630A Abandoned CA2935630A1 (en) | 2014-01-02 | 2015-01-01 | Frizzled receptor antibodies for treatment of cancer |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10465004B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3089995A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017506214A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2935630A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL246540A0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015101998A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3089995A4 (en) | 2014-01-02 | 2017-11-29 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Frizzled receptor antibodies for treatment of cancer |
| WO2017100154A1 (en) * | 2015-12-07 | 2017-06-15 | Purdue Research Foundation | Inhibitors for proliferating cell nuclear antigen and uses |
| CN112159474B (zh) * | 2019-11-06 | 2021-11-19 | 上海健康医学院 | 一种靶向Frizzled7人源化抗体及其制备方法与应用 |
| WO2026051924A1 (zh) * | 2024-09-03 | 2026-03-12 | 浙江道尔生物科技有限公司 | 抗fzd7单域抗体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7867705B2 (en) * | 2004-09-21 | 2011-01-11 | Rhode Island Hospital, A Lifespan-Partner | Frizzled proteins and detection and treatment of cancer |
| EP2500360B1 (en) * | 2005-10-31 | 2015-08-05 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| EP2331136B1 (en) * | 2008-09-26 | 2018-01-10 | OncoMed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| WO2011004379A1 (en) * | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
| EP3089995A4 (en) | 2014-01-02 | 2017-11-29 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Frizzled receptor antibodies for treatment of cancer |
-
2015
- 2015-01-01 EP EP15733130.7A patent/EP3089995A4/en not_active Withdrawn
- 2015-01-01 JP JP2016544451A patent/JP2017506214A/ja active Pending
- 2015-01-01 CA CA2935630A patent/CA2935630A1/en not_active Abandoned
- 2015-01-01 WO PCT/IL2015/050009 patent/WO2015101998A1/en not_active Ceased
- 2015-01-01 US US15/109,173 patent/US10465004B2/en not_active Expired - Fee Related
-
2016
- 2016-06-30 IL IL246540A patent/IL246540A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015101998A1 (en) | 2015-07-09 |
| EP3089995A1 (en) | 2016-11-09 |
| US20160326245A1 (en) | 2016-11-10 |
| IL246540A0 (en) | 2016-08-31 |
| EP3089995A4 (en) | 2017-11-29 |
| JP2017506214A (ja) | 2017-03-02 |
| US10465004B2 (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9109024B2 (en) | Anti-RSPO1 antibodies and uses thereof | |
| US9598497B2 (en) | RSPO3 binding agents and uses thereof | |
| AU2011205409B2 (en) | Wnt-binding agents and uses thereof | |
| DK2481756T3 (en) | Compositions and Methods for Diagnosing and Treating Cancer | |
| MX2012011323A (es) | Agentes que se unen al receptor encrespado y usos de los mismos. | |
| US20170266276A1 (en) | Combination Therapy For Treatment of Cancer | |
| US20170247465A1 (en) | Combination therapy for treatment of cancer | |
| US10465004B2 (en) | Frizzled receptor antibodies for treatment of cancer | |
| US20170247437A1 (en) | Rspo1 binding agents and uses thereof | |
| HK1178915A (en) | Wnt-binding agents and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20210831 |